CD20-directed Cytolytic Antibody class drugs

7 results

  • briumvi

    (ublituximab)
    TG Therapeutics, Inc.
    BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

  • gazyva

    (obinutuzumab)
    Genentech, Inc.
    GAZYVA is indicated for the treatment of previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil. It is also indicated for follicular lymphoma (FL) in patients relapsed or refractory to rituximab, and for untreated stage II bulky, III, or IV FL in combination with chemotherapy.

  • kesimpta

    (ofatumumab)
    Novartis Pharmaceuticals Corporation
    KESIMPTA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

  • ocrevus

    (ocrelizumab)
    Genentech, Inc.
    OCREVUS is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as for primary progressive MS in adults.

  • rituxan

    (rituximab)
    Genentech, Inc.
    RITUXAN is indicated for the treatment of various conditions including Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV) in adults and pediatric patients, as specified.

  • rituxan hycela

    (rituximab and hyaluronidase)
    Genentech, Inc.
    RITUXAN HYCELA is indicated for adults with relapsed/refractory follicular lymphoma, untreated follicular lymphoma with chemotherapy, non-progressing follicular lymphoma after initial CVP chemotherapy, untreated diffuse large B-cell lymphoma with CHOP, and chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide.

  • ruxience

    (rituximab-pvvr)
    Pfizer Laboratories Div Pfizer Inc
    RUXIENCE is indicated for adult patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis, often in combination with other therapies, depending on the specific condition and patient response.